Lyell Immunopharma Inc
LYEL
NASDAQ
Biotechnology
$13.95
USD
+0.21 (+1.53%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $336.70M
Volume 106.1K
Revenue
$27,000
TTM
-55.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-248.48M
TTM
+25.0%
YoY
Operating Cash Flow
$-133.26M
TTM
+22.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -38.5% | -55.9% | -45.5% | -71.4% | -50.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 9.8 | 10.7 | 10.6 | 9.6 | 9.6 |
Other Operating Expenses | 2.5 | -1.6 | 67.0 | -1.9 | -1.8 |
Total Operating Expenses | 47.1 | 37.3 | 129.8 | 44.3 | 47.3 |
Operating Income | -47.1 | -37.3 | -129.8 | -44.3 | -47.3 |
EBITDA | -42.6 | -34.7 | -61.1 | -41.9 | -45.1 |
Other Income / Expense | 1.2 | -4.9 | -13.6 | 17.9 | 0.4 |
Total Other Income / Expense | 4.5 | -1.6 | -10.9 | 20.1 | 2.6 |
Income Before Income Taxes | -42.7 | -38.8 | -140.7 | -24.2 | -44.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -42.7 | -38.8 | -140.7 | -24.2 | -44.8 |
Consolidated Net Income / Loss | -42.7 | -38.8 | -140.7 | -24.2 | -44.8 |
Net Income Attributable to Common Shareholders | -42.7 | -38.8 | -140.7 | -24.2 | -44.8 |
Basic EPS | -$2.89 | -$2.13 | -$6.85 | -$1.10 | -$1.92 |
Diluted EPS | -$2.89 | -$2.13 | -$6.85 | -$1.10 | -$1.92 |
Basic Shares Outstanding | 14.8M | 18.3M | 20.6M | 21.9M | 23.4M |
Diluted Shares Outstanding | 14.8M | 18.3M | 20.6M | 21.9M | 23.4M |